Skip to content

Immix Biopharma, Inc. IMMX Ratios & Valuation

FY'25FY'24FY'23FY'22
Returns
Return on equity-54.9%+90.8pp-145.8%-41.4pp-104.4%-51.5pp-52.8%
Return on assets-46%+54.8pp-100.8%-12.3pp-88.6%-38.8pp-49.7%+211pp
Liquidity
Current ratio10×+7.7×2.3×-3.0×5.3×-6.4×11.7×-78.3×
Quick ratio10×+7.7×2.3×-3.0×5.3×-6.4×11.7×-78.3×
Cash ratio9.3×+7.3×-2.7×4.7×-5.8×10.6×-76.8×
Leverage
Debt-to-equity-0.1×0.1×
Debt-to-assets0.0×
Per Share
Book value per share$2.85+507%$0.47-50.5%$0.95-0.2%$0.95-80.7%
Valuation
Market capitalization$691.97M+1,008%$60.52M-56.1%$137.86M+355%$30.29M-38.5%
Enterprise value$613.75M+1,190%$43.91M
Price / book8.2×+1.7×4.6×-3.8×8.4×+6.1×2.3×-0.4×
Free cash flow yield-4.7%+16.7pp-26.1%
Earnings yield-5%+28.4pp-35.7%-24.5pp-11.2%+16.0pp-27.2%+22.4pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Immix Biopharma, Inc.'s ratios come from?
Every ratio is computed from Immix Biopharma, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.